Jaume Pons

Dr. Pons previously served as Chief Scientific Officer and site head of Rinat (Pfizer), where he was responsible for portfolio delivery from idea to clinical development. He implemented the vision of a company unit following biology across therapeutic areas while generating advanced antibody technologies, and turned Rinat into the center of cancer immunology for Pfizer. Dr. Pons is an inventor of three antibodies in late-stage clinical development and has advanced nine additional antibodies into human trials in multiple therapeutic areas. As Senior Vice President of R&D, he was a member of Pfizer’s World R&D Leadership Team. Before Pfizer, Dr. Pons created and led Rinat’s protein engineering group and was a scientist at Chiron.Dr. Pons earned his Ph.D. in Molecular and Cell biology at the Institute on Fundamental Biology, Barcelona, Spain, M.S. in Biotechnology, and B.S. in Biochemistry from Autonoma University of Barcelona. He conducted his postdoctoral studies in antibody engineering at the University of California, Berkeley.

Jaume Pons is the President, Chief Executive Officer and Co-Founder at ALX Oncology. With a background in Biotechnology, Jaume Pons has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.